More than 2 million individuals died as a result of the continuing COVID-19 pandemic. The United States had the largest number of connected fatalities, with over 499,000.
COVID-19 Patients At Home Do Not Need Blood Thinners
While new COVID-19 vaccinations may ultimately help lower the number of fatalities, the very sluggish deployment in many countries has raised worries that meaningful benefits will take longer to manifest.
Doctors began to notice a higher risk of possibly fatal blood clots in individuals hospitalized with severe COVID-19 early in the pandemic, and they frequently began to administer blood thinners in these instances.
When a blood artery is damaged, blood clotting, or coagulation, is a crucial mechanism that avoids excessive bleeding. Platelets, a kind of blood cell, and proteins in plasma collaborate to stop the bleeding by creating a clot over the damage.
After the damage has healed, the body will usually destroy the blood clot on its own. Clots can develop on the interior of vessels without any visible damage and do not dissolve spontaneously. These are potentially hazardous conditions that need a precise diagnosis and suitable treatment.
The danger of symptomatic blood clots, heart attack, stroke, as well as other severe cardiopulmonary problems among individuals with milder COVID-19 is so minimal that blood thinners cannot be justified in these patients, according to the current study.
The findings are extremely encouraging for the millions of patients who are handling mild, stable symptoms of SARS-CoV-2 infections at home, according to study chair Dr. Paul Ridker, head of the Center for Cardiovascular Disease Prevention at Brigham and Women’s Hospital in Boston.
The National Heart, Lung, and Blood Institute of the United States financed the study.
One specialist in the management of COVID-19 patients deemed the findings critical.
They’ve been waiting for these results for a long time, according to Dr. Narasimhan, who is the director of critical care services at Northwell Health, New Hyde Park, New York.
This study demonstrates that patients with mild COVID-19 who are managed at home are not at a greater risk of clots than normal persons and do not require clot-prevention medicines. In this patient population, the dangers of utilizing these medicines outweigh the benefits.
This will transform the way doctors treat mild COVID-19 for the vast majority of patients, she says.
The current research comprised COVID-19 patients who were minimally symptomatic but clinically stable and had been ill at home for at least a week and had no risk factors for blood clots.
They were allocated randomly to either a preventative dosage of the blood thinner drug Apixaban (2.5 milligrams twice daily), a therapeutic dose of Apixaban (5 mg twice daily), low-dose aspirin (81mg once daily), or a placebo twice daily for 45 days.
According to a Brigham & Women’s press release, there have only been a few hospitalizations for COVID-related pneumonia and no thromboembolic clotting events among the patients recruited and taking study medicines during the 45-day trial period were observed.
As blood thinners have their risks of bleeding. The study’s oversight board recommended that the experiment be terminated, resulting in a halt in patient enrolment.
The researchers, however, stated that they will continue to evaluate the participants in the study. The findings have not yet been published, but Ridker’s team has said that they will be further analyzed and submitted for publication in a peer-reviewed journal.
Dr. Jean Connors, study main investigator and hematologist at Brigham and Women’s Hospital, stated, that they routinely receive queries from physicians caring for moderately symptomatic outpatients regarding the best road ahead for these highly prevalent patients. For people who are a week or more past the period of COVID-19 diagnosis, are clinically stable, and do not have additional risk factors, the best course of action is likely not to treat with antithrombotics (blood thinners) unless there are other reasons for such treatment.